Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™

Theo Nicholaou,Weisan Chen,Ian D. Davis,Heather Jackson,Nektaria Dimopoulos,Catherine Barrow,Judy Browning,Duncan MacGregor,David S. Williams,Wendie Hopkins,Eugene Maraskovsky,Ralph Venhaus,Linda Pan,Eric W. Hoffman,Lloyd J. Old,Jonathan Cebon

Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™

2011

Theo Nicholaou
Weisan Chen
Ian D. Davis
Heather Jackson
Nektaria Dimopoulos
Catherine Barrow
Judy Browning
Duncan MacGregor
David S. Williams
Wendie Hopkins
Eugene Maraskovsky
Ralph Venhaus
Linda Pan
Eric W. Hoffman
Lloyd J. Old
Jonathan Cebon

Background NY-ESO-1 protein formulated in ISCOMATRIX™ results in CD4+, CD8+ T cell and antibody-mediated immunity. We evaluated persistence of immunity, relapse-free survival and tumour antigen expression upon relapse in patients vaccinated in an earlier trial.

Keywords:

Immunity
Immunotherapy
NY-ESO-1
Immunoediting
Virology
Immunology
CD8
T cell
Antigen
Cancer vaccine
Medicine
Melanoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations